2014/907/EU: Commission Implementing Decision of 11 December 2014 authorising the placing on the market of Clostridium butyricum (CBM 588) as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council (notified under document C(2014) 9345)
2014/907/EU: Commission Implementing Decision of 11 December 2014 authorising the placing on the market of Clostridium butyricum (CBM 588) as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council (notified under document C(2014) 9345)
Regulation (EC) No 258/97 · Decision · 4 articles
Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗
Clostridium butyricum (CBM 588) as specified in the Annex may be placed on the market in the Union as a novel food ingredient to be used in food supplements with a maximum dose of 1,35 × 10 8 CFU per day without prejudice to the specific provisions of Directive 2002/46/EC.
The designation of Clostridium butyricum (CBM 588) authorised by this Decision on the labelling of the foodstuffs containing it shall be ‘ Clostridium butyricum MIYAIRI 588 (CBM 588)’ or ‘ Clostridium butyricum (CBM 588)’.
ANNEX
SPECIFICATION OF CLOSTRIDIUM BUTYRICUM (CBM 588)
Definition
: Clostridium butyricum (CBM 588) is a Gram-positive, spore-forming, obligate anaerobic, non-pathogenic, non-genetically modified bacterium.
Description
: White or pale grey tablets with characteristic odour and sweet taste.
Microbiological criteria:
Total viable aerobic count
Not more than 10 3 CFU/g
Escherichia coli
Not detected in 1 g
Staphylococcus aureus
Not detected in 1 g
Pseudomonas aeruginosa
Not detected in 1 g
Yeast and moulds
Not more than 10 2 CFU/g